Predicted to be involved in cellular response to retinoic acid; central nervous system neuron development; and negative regulation of mitotic cell cycle. Predicted to act upstream of or within several processes, including behavioral fear response; maternal behavior; and short-term memory. Predicted to be active in cytoplasm; dendrite; and neuronal cell body. Orthologous to human BRINP1 (BMP/retinoic acid inducible neural specific 1); INTERACTS WITH 3,3',4,4',5-pentachlorobiphenyl; 4,4'-sulfonyldiphenol; 6-propyl-2-thiouracil.
BMP/retinoic acid-inducible neural-specific protein; BMP/retinoic acid-inducible neural-specific protein 1; bone morphogenetic protein/retinoic acid inducible neural-specific 1; bone morphogenic protein/retinoic acid inducible neural-specific 1; Dbc1; Dbccr1; deleted in bladder cancer 1; deleted in bladder cancer 1 (human); deleted in bladder cancer chromosome region candidate 1; deleted in bladder cancer chromosome region candidate 1 (human); deleted in bladder cancer protein 1 homolog; LOC140610
[Decitabine co-treated with trichostatin A] inhibits the reaction [sodium arsenite affects the methylation of BRINP1 promoter], Decitabine inhibits the reaction [sodium arsenite affects the methylation of BRINP1 promoter]
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRINP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRINP1 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRINP1 mRNA